Battelle Ventures
VC Fund
Trenton, United States
Battelle Ventures is a VC fund in Trenton focused on Biotechnology and Health Care. Battelle Ventures, L.P., and its affiliate fund, Innovation Valley Partners (IVP), have a combined $255 million under management to create and accelerate the development of early-stage technology companies with breakthrough solutions to key market problems.The funds enjoy close relationships with the technology transfer offices of the NationalLaboratories that Battelle Memorial Institute (Battelle) manages or co-manages for the U.S. Department of Energy. They also have established similar associations with a number of university tech transfer and commercialization departments.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Battelle Ventures invests in
BiotechnologyHealth CareSoftwareTherapeuticsManufacturing
Stages Battelle Ventures invests in
Series BSeries ASeries CFunding Round
Countries Battelle Ventures invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Mort Collins
|
|||
|
Ralph E. Taylor-Smith
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 5 (33%)
- Health Care 3 (20%)
- Software 2 (13%)
- Therapeutics 2 (13%)
- Manufacturing 2 (13%)
Stage
- Series B 6 (40%)
- Series A 3 (20%)
- Series C 2 (13%)
- Funding Round 2 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Mort Collins
General Partner
|
General Partner | Total investments: 0 | Find email | |
|
Ralph E. Taylor-Smith
General Partner
|
General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Bionano Genomics
|
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $53M / Series C / Nov 20, 2014 | |
|
Bionano Genomics
|
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $10M / Series C / Oct 02, 2013 | |
|
Bionano Genomics
|
Bionano Genomics is a biotechnology company that specializes in genome mapping and analysis. The company develops and markets the Saphyr system, which is a platform for ultra-sensitive and ultra-specific structural variation detection in DNA. Structural variations are alterations in the DNA structure, such as insertions, deletions, inversions, andtranslocations, that can be associated with various genetic disorders and diseases, including cancer.Bionano Genomics' Saphyr system uses a technology called optical genome mapping (OGM) to analyze long DNA molecules. OGM allows for the direct visualization and analysis of structural variations in the genome without the need for sequencing. This technology can provide valuable insights into the structural variations in an individual's genome, which can be important for understanding disease mechanisms, and genetic disorders, and for guiding personalized treatment strategies. | $10M / Series B / Jul 06, 2012 | |
GRIDSMART Technologies
|
Aldis, Inc., a CleanTech company, develops, commercializes, and sells traffic and energy management technology and services to municipal partners. The company offers GridSmart, a vision-based traffic monitoring and control system. Its GridSmart line of products include Spectra 360, a single-camera solution that sees in various directions; GridSmartOptima 360, which provides stop-bar detection, as well as vehicle counting, speed, and classification; GridSmart Ultra 360, which tracks vehicle speed, turn and pedestrian counts, emergency vehicle preemption modes, machine-enabled red light mitigation, and real-time video feeds; GridSmart XPress, a freeway monitoring system to view and track vehicles and provides traffic control center with vehicle counts and average speeds; and GridSmart Centrex, a smart parking system. The company also provides SmartWay, a line of products that provide energy efficient LED traffic signals. In addition, its solutions include vehicle/turn counts, red light runner (RLR) mitigation, auto alerts, pedestrian tracking, and software upgrades. The company serves transportation logistics and advanced infrastructure management markets. Aldis, Inc. was founded in 2006 and is based in Oak Ridge, Tennessee. | $6M / Aug 22, 2010 | |
NuPathe
|
NuPathe Inc. is a specialty pharmaceutical company focused on innovative neuroscience solutions for diseases of the central nervous system including neurological and psychiatric disorders. NuPathe's lead product candidate, NP101, is an active, single-use, transdermal sumatriptan patch being developed for the treatment of migraine. In additionto NP101, NuPathe has two proprietary product candidates based on its LAD™, or Long-Acting Delivery, biodegradable implant technology that allows delivery of therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes a leading FDA-approved dopamine agonist, ropinirole, and is being developed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is being developed to address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an atypical antipsychotic. NuPathe is actively seeking partnerships to maximize the commercial potential for its product candidates in the U.S. and territories throughout the world. | $30M / Series B / Jul 24, 2008 | |
|
GRIDSMART Technologies
|
Aldis, Inc., a CleanTech company, develops, commercializes, and sells traffic and energy management technology and services to municipal partners. The company offers GridSmart, a vision-based traffic monitoring and control system. Its GridSmart line of products include Spectra 360, a single-camera solution that sees in various directions; GridSmartOptima 360, which provides stop-bar detection, as well as vehicle counting, speed, and classification; GridSmart Ultra 360, which tracks vehicle speed, turn and pedestrian counts, emergency vehicle preemption modes, machine-enabled red light mitigation, and real-time video feeds; GridSmart XPress, a freeway monitoring system to view and track vehicles and provides traffic control center with vehicle counts and average speeds; and GridSmart Centrex, a smart parking system. The company also provides SmartWay, a line of products that provide energy efficient LED traffic signals. In addition, its solutions include vehicle/turn counts, red light runner (RLR) mitigation, auto alerts, pedestrian tracking, and software upgrades. The company serves transportation logistics and advanced infrastructure management markets. Aldis, Inc. was founded in 2006 and is based in Oak Ridge, Tennessee. | $3.8M / Series A / Oct 22, 2007 | |
Metatomix
|
Metatomix was founded in 2000 and describes themselves as the "semantic integration provider." Metatomix' solutions aim to link data from "existing disparate systems to create a common semantic understanding of your information across the enterprise, providing you a 360° view of your business information. As a result, businessapplications can leverage information that comes not just from a single product system or data store, but from across all data sources." | $7M / Series B / May 22, 2007 | |
Rajant Corporation
|
$3.3M / Series B / Jul 24, 2006 | ||
BioVigilant Systems
|
BioVigilant Systems invented instantaneous microbial detection technology to address environmental monitoring needs in pharmaceutical, biotechnology, healthcare, and environmental applications. BioVigilant’s IMD systems detect—instantaneously and in real time—particulate count, size, and biological status. Unlike other rapid microbialmethods, BioVigilant’s optically-based systems require no staining, no reagents, no waiting period, and little human intervention. | $6.7M / Series A / May 23, 2006 | |
Ventaira Pharmaceuticals
|
Ventaira Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development of new inhalation products by utilizing its novel proprietary electrohydrodynamic (EHD) aerosolization and formulation technologies. | $13.5M / Series C / Apr 05, 2005 | |
| See all 15 investments → | |||
Co-Investors
Innovation Valley Partners
4 deals together
Domain Associates
3 deals together
Meritus Ventures
2 deals together
Safeguard Scientifics
2 deals together
Apex Venture Partners
1 deal together
Bay City Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Climate Investors
40,325 investors
Manufacturing Investors
24,696 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
FAQ
What does Battelle Ventures invest in?
Battelle Ventures invests primarily in Biotechnology, Health Care and Software startups, most often at Series B and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Battelle Ventures?
Public channels for Battelle Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Battelle Ventures?
The team at Battelle Ventures includes Mort Collins (General Partner) and Ralph E. Taylor-Smith (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
